MYBL2 (Gene)

Organism:

Homo sapiens

Synonyms:B-MYB, BMYB, ENTREZ:4605, HGNC:7548, MIM:601415, MYB proto-oncogene like 2, MYBL2, NM_001278610, NM_002466, NP_001265539, NP_002457

Omim:OMIM:601415

Id:ENSG00000101057

Hgnc:HGNC:7548

Entrez:4605

Ensembl:ENSG00000101057

Description:MYB proto-oncogene like 2

The protein encoded by this gene, a member of the MYB family of transcription factor genes, is a nuclear protein involved in cell cycle progression. The encoded protein is phosphorylated by cyclin A/cyclin-dependent kinase 2 during the S-phase of the cell cycle and possesses both activator and repressor activities. It has been shown to activate the cell division cycle 2, cyclin D1, and insulin-like growth factor-binding protein 5 genes. Two transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2013]

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View MYBL2's neighborhood in the knowledge graph.

Submit

Playbook Workflow Builder: Gene-Centric Workflow

View Gene-Centric information about the gene from a pre-built PWB workflow. View the workflow with MYBL2.

CFDE Gene-Centric Appyter

The CFDE Gene Centric Appyter Resolves and Displays Gene-Centric information from CFDE APIs. Execute the Appyter using MYBL2.

Submit

GDLPA Landing Pages Links

The Gene and Drug Landing Page Aggregator (GDLPA) finds links to primary and secondary source information from CFDE and other resources. Discover landing pages for MYBL2.

Submit

Playbook Workflow Builder

The Playbook Workflow Builder helps you interactively construct workflows leveraging CFDE APIs without code. Start a new workflow with MYBL2.

Results found

Linked to

	Label	Description
	GSE166914 1 V 2 ABEMACICLIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE252944 AKT inhibition 10 v 15 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE216043 10 V 5 CISPLATIN HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE220806 1 V 3 PROGESTERONE HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 8 V 7 SAHA HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS
	GSE248769 1 V 0 SORAFENIB HUMAN UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP Gene Set (Entity type)	A Gene Set from LINCS
	GSE213588 9 V 13 TRAMETINIB HUMAN DN Gene Set (Entity type)	A Gene Set from LINCS

GSE166914 1 V 2 ABEMACICLIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE252944 AKT inhibition 10 v 15 human dn

Gene Set (Entity type)

A Gene Set from LINCS

GSE226525 GSE226527 HNRNPH2 knockout 6 v 5 human up

Gene Set (Entity type)

A Gene Set from LINCS

GSE216043 10 V 5 CISPLATIN HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE110178 2 V 3 TRANYLCYPROMINE MOUSE DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE220806 1 V 3 PROGESTERONE HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE77108 8 V 7 SAHA HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

GSE248769 1 V 0 SORAFENIB HUMAN UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE128240 0 V 1 CYCLOPHOSPHAMIDE MOUSE UP

Gene Set (Entity type)

A Gene Set from LINCS

GSE213588 9 V 13 TRAMETINIB HUMAN DN

Gene Set (Entity type)

A Gene Set from LINCS

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.